Top

Published in:

01-12-2008 | Original Paper

Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy

Authors: Sina Nettekoven, Alexander Ströhle, Birgit Trunz, Maike Wolters, Susanne Hoffmann, Rüdiger Horn, Martin Steinert, Georg Brabant, Ralf Lichtinghagen, Hans-Jürgen Welkoborsky, Ingrid Tuxhorn, Andreas Hahn

Published in: European Journal of Pediatrics | Issue 12/2008

Abstract

Reports of decreased serum 25-hydroxyvitamin D (25-OHD) and altered bone metabolism associated with antiepileptic drug (AED) treatment are inconsistent and predominantly restricted to adults. In this cross-sectional observational study, the aim was to evaluate the influence of AED treatment on vitamin D status and markers of bone turnover in children with epilepsy. In 38 children taking AEDs and 44 healthy control subjects, blood samples were collected to determine the levels of serum 25-OHD, intact parathyroid hormone (iPTH), calcium (Ca), phosphate (P), bone alkaline phosphatase (BAP), osteocalcin (OC) and C terminal telopeptide of type I collagen (ICTP). More than 75% of the patients were vitamin D deficient (serum 25-OHD<20 ng/mL) and 21% of the patients had an insufficient vitamin D status (serum 25-OHD=20–30 ng/mL). In the patients, the serum levels of OC (p = 0.002) and BAP (p < 0.001) were significantly increased, but ICTP (p = 0.002) concentrations were significantly decreased compared with the control group. When patients where divided into two groups according to their medication (mono- or polytherapy), significantly lower 25-OHD (p = 0.038) and ICTP (p = 0.005) levels and elevated BAP (p = 0.023) concentrations were found in patients under polytherapy. An association between 25-OHD and the measured bone markers could not be determined. Our results indicate that the prevalence of vitamin D deficiency in epilepsy patients under AED treatment is high, especially under polytherapy, and alteration markers of bone formation and resorption suggests an accelerated skeletal turnover. The routine monitoring of serum 25-OHD and vitamin D supplementation on an individual basis should be considered.

Akin R, Okutan V, Sarici U, Altunbas A, Gökçay E (1998) Evaluation of bone mineral density in children receiving antiepileptic drugs. Pediatr Neurol 19:129–131PubMedCrossRef

Andersen R, Molgaard C, Skovgaard LT, Brot C, Cashman KD, Jakobsen J, Lamberg-Allardt C, Ovesen L (2007) Pakistani immigrant children and adults in Denmark have severely low vitamin D status. Eur J Clin Nutr [Epub ahead of print]

Andress DL, Ozuna J, Tirschwell D, Grande L, Johnson M, Jacobson AF, Spain W (2002) Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol 59:781–786PubMedCrossRef

Attilakos A, Garoufi A, Voudris K, Mastroyianni S, Fotinou A, Papadimitriou DT, Gavalakis N, Prassouli A, Katsarou E (2007) Thyroid dysfunction associated with increased low-density lipoprotein cholesterol in epileptic children treated with carbamazepine monotherapy: a causal relationship? Eur J Paediatr Neurol 11:358–361PubMedCrossRef

Attilakos A, Papakonstantinou E, Schulpis K, Voudris K, Katsarou E, Mastroyianni S, Garoufi A (2006) Early effect of sodium valproate and carbamazepine monotherapy on homocysteine metabolism in children with epilepsy. Epilepsy Res 71:229–232PubMedCrossRef

Baer MT, Kozlowski BW, Blyler EM, Trahms CM, Taylor ML, Hogan MP (1997) Vitamin D, calcium, and bone status in children with developmental delay in relation to anticonvulsant use and ambulatory status. Am J Clin Nutr 65:1042–1051PubMed

Bergqvist AG, Schall JI, Stallings VA (2007) Vitamin D status in children with intractable epilepsy, and impact of the ketogenic diet. Epilepsia 48:66–71PubMedCrossRef

Bischoff-Ferrari HA (2007) The 25-hydroxyvitamin D threshold for better health. J Steroid Biochem Mol Biol 103:614–619PubMedCrossRef

Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B (2006) Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 84:18–28PubMed

10.

Bloomfield SA, Mysiw WJ, Jackson RD (1996) Bone mass and endocrine adaptations to training in spinal cord injured individuals. Bone 19:61–68PubMedCrossRef

11.

Bradney M, Pearce G, Naughton G, Sullivan C, Bass S, Beck T, Carlson J, Seeman E (1998) Moderate exercise during growth in prepubertal boys: changes in bone mass, size, volumetric density, and bone strength: a controlled prospective study. J Bone Miner Res 13:1814–1821PubMedCrossRef

12.

Brown SJ (2006) The role of vitamin D in multiple sclerosis. Ann Pharmacother 40:1158–1161PubMedCrossRef

13.

Cheng S, Tylavsky F, Kröger H, Kärkkäinen M, Lyytikäinen A, Koistinen A, Mahonen A, Alen M, Halleen J, Väänänen K, Lamberg-Allardt C (2003) Association of low 25-hydroxyvitamin D concentrations with elevated parathyroid hormone concentrations and low cortical bone density in early pubertal and prepubertal Finnish girls. Am J Clin Nutr 78:485–492PubMed

14.

Christiansen C, Rødbro P, Tjellesen L (1983) Pathophysiology behind anticonvulsant osteomalacia. Acta Neurol Scand Suppl 94:21–28PubMed

15.

Cowan LD (2002) The epidemiology of the epilepsies in children. Ment Retard Dev Disabil Res Rev 8:171–181PubMedCrossRef

16.

Davie MW, Emberson CE, Lawson DE, Roberts GE, Barnes JL, Barnes ND, Heeley AF (1983) Low plasma 25-hydroxyvitamin D and serum calcium levels in institutionalized epileptic subjects: associated risk factors, consequences and response to treatment with vitamin D. Q J Med 52:79–91PubMed

17.

Delmas PD (1995) Biochemical markers of the assessment of bone turnover. In: Riggs BL, Melton LJ (eds) Osteoporosis: etiology, diagnosis and management, 2nd edn. Lippincott-Raven, Philadelphia, pp 319–333

18.

Dent CE, Richens A, Rowe DJF, Stamp TCB (1970) Osteomalacia with long-term anticonvulsant therapy in epilepsy. Br Med J 4:69–72PubMed

19.

Eiris J, Novo-Rodríguez MI, Del Río M, Meseguer P, Del Río MC, Castro-Gago M (2000) The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy. Epilepsy Res 41:1–7PubMedCrossRef

20.

Feldkamp J, Becker A, Witte OW, Scharff D, Scherbaum WA (2000) Long-term anticonvulsant therapy leads to low bone mineral density—evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes 108:37–43PubMed

21.

Fitzpatrick LA (2004) Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy Behav 5(Suppl 2):S3–S15PubMedCrossRef

22.

Ginty F, Cavadini C, Michaud PA, Burckhardt P, Baumgartner M, Mishra GD, Barclay DV (2004) Effects of usual nutrient intake and vitamin D status on markers of bone turnover in Swiss adolescents. Eur J Clin Nutr 58:1257–1265PubMedCrossRef

23.

Gissel T, Poulsen CS, Vestergaard P (2007) Adverse effects of antiepileptic drugs on bone mineral density in children. Expert Opin Drug Saf 6:267–278PubMedCrossRef

24.

Gosling P (1986) Analytical reviews in clinical biochemistry: calcium measurement. Ann Clin Biochem 23:146–156PubMed

25.

Gough H, Goggin T, Bissessar A, Baker M, Crowley M, Callaghan N (1986) A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy. Q J Med 59:569–577PubMed

26.

Grant WB, Holick MF (2005) Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev 10:94–111PubMed

27.

Guo CY, Ronen GM, Atkinson SA (2001) Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 42:1141–1147PubMedCrossRef

28.

Hahn TJ, Hendin BA, Scharp CR, Boisseau VC, Haddad JG (1975) Serum 25-hydroxycalciferol levels and bone mass in children on chronic anticonvulsant therapy. N Engl J Med 292:550–554CrossRef

29.

Harms HM, Schlinke E, Neubauer O, Kayser C, Wüstermann PR, Horn R, Külpmann WR, von zur Mühlen A, Hesch RD (1994) Pulse amplitude and frequency modulation of parathyroid hormone in primary hyperparathyroidism. J Clin Endocrinol Metab 78:53–57PubMedCrossRef

30.

Hintzpeter B, Mensink GB, Thierfelder W, Müller MJ, Scheidt-Nave C (2007) Vitamin D status and health correlates among German adults. Eur J Clin Nutr [Epub ahead of print]

31.

Hoikka V, Savolainen K, Alhava EM, Sivenius J, Karjalainen P, Repo A (1981) Osteomalacia in institutionalized epileptic patients on long-term anticonvulsant therapy. Acta Neurol Scand 64:122–131PubMedCrossRef

32.

Holick MF (1994) McCollum award lecture, 1994: Vitamin D—new horizons for the 21st century. Am J Clin Nutr 60:619–630PubMed

33.

Holick MF (2006) The role of vitamin D for bone health and fracture prevention. Curr Osteoporos Rep 4:96–102PubMedCrossRef

34.

Hunter J, Maxwell JD, Stewart DA, Parsons V, Williams R (1971) Altered calcium metabolism in epileptic children on anticonvulsants. Br Med J 23:202–204

35.

Kafali G, Erselcan T, Tanzer F (1999) Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. Clin Pediatr (Phila) 38:93–98CrossRef

36.

Kalueff AV, Minasyan A, Tuohimaa P (2005) Anticonvulsant effects of 1,25-dihydroxyvitamin D in chemically induced seizures in mice. Brain Res Bull 67:156–160PubMedCrossRef

37.

Karabiber H, Sonmezgoz E, Ozerol E, Yakinci C, Otlu B, Yologlu S (2003) Effects of valproate and carbamazepine on serum levels of homocysteine, vitamin B12, and folic acid. Brain Dev 25:113–115PubMedCrossRef

38.

Kaushik A, Sehgal H, Kumar R (1982) Altered vitamin-D metabolism due to anticonvulsant drugs in epileptic children. Indian Pediatr 19:489–492PubMed

39.

Krause KH, Berlit P, Bonjour JP, Schmidt-Gayk H, Schellenberg B, Gillen J (1982) Vitamin status in patients on chronic anticonvulsant therapy. Int J Vitam Nutr Res 52:375–385PubMed

40.

Krause KH, Bonjour JP, Berlit P, Kynast G, Schmidt-Gayk H, Arab L (1986) B vitamins in epileptics. Bibl Nutr Dieta 38:154–167PubMed

41.

Krause KH, Bonjour JP, Berlit P, Kynast G, Schmidt-Gayk H, Schellenberg B (1988) Effect of long-term treatment with antiepileptic drugs on the vitamin status. Drug Nutr Interact 5:317–343PubMed

42.

Kruse K, Kracht U, Göpfert G (1982) Response of kidney and bone to parathyroid hormone in children receiving anticonvulsant drugs. Neuropediatrics 13:3–9PubMedCrossRef

43.

Kulak CA, Borba VZ, Bilezikian JP, Silvado CE, Paola L, Boguszewski CL (2004) Bone mineral density and serum levels of 25 OH vitamin D in chronic users of antiepileptic drugs. Arq Neuropsiquiatr 62:940–948PubMed

44.

Lehtonen-Veromaa MK, Möttönen TT, Nuotio IO, Irjala KM, Leino AE, Viikari JS (2002) Vitamin D and attainment of peak bone mass among peripubertal Finnish girls: a 3-y prospective study. Am J Clin Nutr 76:1446–1453PubMed

45.

Mark BL, Carson JA (2006) Vitamin D and autoimmune disease—implications for practice from the multiple sclerosis literature. J Am Diet Assoc 106:418–424PubMedCrossRef

46.

Mintzer S, Boppana P, Toguri J, DeSantis A (2006) Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 47:510–515PubMedCrossRef

47.

Morijiri Y, Sato T (1981) Factors causing rickets in institutionalised handicapped children on anticonvulsant therapy. Arch Dis Child 56:446–449PubMed

48.

Nakamura K, Nashimoto M, Matsuyama S, Yamamoto M (2001) Low serum concentrations of 25-hydroxyvitamin D in young adult Japanese women: a cross sectional study. Nutrition 17:921–925PubMedCrossRef

49.

Nakamura K, Ueno K, Nishiwaki T, Okuda Y, Saito T, Tsuchiya Y, Yamamoto M (2005) Nutrition, mild hyperparathyroidism, and bone mineral density in young Japanese women. Am J Clin Nutr 82:1127–1133PubMed

50.

Nicolaidou P, Georgouli H, Kotsalis H, Matsinos Y, Papadopoulou A, Fretzayas A, Syriopoulou V, Krikos X, Karantana A, Karpathios T (2006) Effects of anticonvulsant therapy on vitamin D status in children: prospective monitoring study. J Child Neurol 21:205–209PubMed

51.

Nordström P, Lorentzon R (1999) Influence of heredity and environment on bone density in adolescent boys: a parent-offspring study. Osteoporos Int 10:271–277PubMedCrossRef

52.

Öner N, Kaya M, Karasalihoğlu S, Karaca H, Celtik C, Tütüncüler F (2004) Bone mineral metabolism changes in epileptic children receiving valproic acid. J Paediatr Child Health 40:470–473PubMedCrossRef

53.

Outila TA, Kärkkäinen MU, Lamberg-Allardt CJ (2001) Vitamin D status affects serum parathyroid hormone concentrations during winter in female adolescents: associations with forearm bone mineral density. Am J Clin Nutr 74:206–210PubMed

54.

Pascussi JM, Robert A, Nguyen M, Walrant-Debray O, Garabedian M, Martin P, Pineau T, Saric J, Navarro F, Maurel P, Vilarem MJ (2005) Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 115:177–186PubMed

55.

Petty SJ, O’Brien TJ, Wark JD (2007) Anti-epileptic medication and bone health. Osteoporos Int 18:129–142PubMedCrossRef

56.

Ponsonby AL, Lucas RM, van der Mei IA (2005) UVR, vitamin D and three autoimmune diseases—multiple sclerosis, type 1 diabetes, rheumatoid arthritis. Photochem Photobiol 81:1267–1275PubMedCrossRef

57.

Rieger-Wettengl G, Tutlewski B, Stabrey A, Rauch F, Herkenrath P, Schauseil-Zipf U, Schoenau E (2001) Analysis of the musculoskeletal system in children and adolescents receiving anticonvulsant monotherapy with valproic acid or carbamazepine. Pediatrics 108:E107PubMedCrossRef

58.

Sato Y, Kondo I, Ishida S, Motooka H, Takayama K, Tomita Y, Maeda H, Satoh K (2001) Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 14(57):445–449

59.

Sheth RD, Wesolowski CA, Jacob JC, Penney S, Hobbs GR, Riggs JE, Bodensteiner JB (1995) Effect of carbamazepine and valproate on bone mineral density. J Pediatr 127:256–262PubMedCrossRef

60.

Shinnar S, Pellock JM (2002) Update on the epidemiology and prognosis of pediatric epilepsy. J Child Neurol 17(Suppl 1):S4–S17PubMedCrossRef

61.

Sonmez FM, Demir E, Orem A, Yildirmis S, Orhan F, Aslan A, Topbas M (2006) Effect of antiepileptic drugs on plasma lipids, lipoprotein (a), and liver enzymes. J Child Neurol 21:70–74PubMedCrossRef

62.

Sözüer DT, Atakil D, Dogu O, Baybas S, Arpaci B (1997) Serum lipids in epileptic children treated with carbamazepine and valproate. Eur J Pediatr 156:565–567PubMedCrossRef

63.

Tsai KS, Lin JC, Chen CK, Cheng WC, Yang CH (1997) Effect of exercise and exogenous glucocorticoid on serum level of intact parathyroid hormone. Int J Sports Med 18:583–587PubMedCrossRef

64.

Välimäki MJ, Tiihonen M, Laitinen K, Tähtelä R, Kärkkäinen M, Lamberg-Allardt C, Mäkelä P, Tunninen R (1994) Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 9:631–637PubMedCrossRef

65.

Valsamis HA, Arora SK, Labban B, McFarlane SI (2006) Antiepileptic drugs and bone metabolism. Nutr Metab (Lond) 6:36CrossRef

66.

Vernillo AT, Rifkin BR, Hauschka PV (1990) Phenytoin affects osteocalcin secretion from osteoblastic rat osteosarcoma 17/2.8 cells in culture. Bone 11:309–312PubMedCrossRef

67.

Verrotti A, Greco R, Latini G, Morgese G, Chiarelli F (2002) Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 43:1488–1492PubMedCrossRef

68.

Verrotti A, Greco R, Morgese G, Chiarelli F (2000) Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 47:385–388PubMedCrossRef

69.

Vieth R (2004) Why the optimal requirement for Vitamin D3 is probably much higher than what is officially recommended for adults. J Steroid Biochem Mol Biol 89–90:575–579PubMedCrossRef

70.

Vieth R (2006) What is the optimal vitamin D status for health? Prog Biophys Mol Biol 92:26–32PubMedCrossRef

71.

Vieth R, Chan PC, MacFarlane GD (2001) Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 73:288–294PubMed

72.

Voudris KA, Attilakos A, Katsarou E, Drakatos A, Dimou S, Mastroyianni S, Skardoutsou A, Prassouli A, Garoufi A (2006) Early and persistent increase in serum lipoprotein (a) concentrations in epileptic children treated with carbamazepine and sodium valproate monotherapy. Epilepsy Res 70:211–217PubMedCrossRef

73.

Voudris K, Moustaki M, Zeis PM, Dimou S, Vagiakou E, Tsagris B, Skardoutsou A (2002) Alkaline phosphatase and its isoenzyme activity for the evaluation of bone metabolism in children receiving anticonvulsant monotherapy. Seizure 11:377–380PubMedCrossRef

74.

Weisman SM, Matkovic V (2005) Potential use of biochemical markers of bone turnover for assessing the effect of calcium supplementation and predicting fracture risk. Clin Ther 27:299–308PubMedCrossRef

75.

Winnacker JL, Yeager H, Saunders JA, Russell B, Anast CS (1977) Rickets in children receiving anticonvulsant drugs. Biochemical and hormonal markers. Am J Dis Child 131:286–290PubMed

76.

Zhou C, Assem M, Tay JC, Watkins PB, Blumberg B, Schuetz EG, Thummel KE (2006) Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest 116:1703–1712PubMedCrossRef

Title: Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy
Authors: Sina Nettekoven
Alexander Ströhle
Birgit Trunz
Maike Wolters
Susanne Hoffmann
Rüdiger Horn
Martin Steinert
Georg Brabant
Ralf Lichtinghagen
Hans-Jürgen Welkoborsky
Ingrid Tuxhorn
Andreas Hahn
Publication date: 01-12-2008
Publisher: Springer-Verlag
Published in: European Journal of Pediatrics / Issue 12/2008
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-008-0672-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2008

TNF receptor-associated periodic syndrome (TRAPS): Description of a novel TNFRSF1A mutation and response to etanercept

Severe neonatal hypercalcemia caused by subcutaneous fat necrosis without any apparent cutaneous lesion

Outbreaks of human coronavirus in a paediatric and neonatal intensive care unit

An unusual complication of umbilical catheterisation

Clinical and radiological findings in Schinzel–Giedion syndrome

Defining chronic diseases and health conditions in childhood (0–18 years of age): national consensus in the Netherlands